Third Circuit Affirms Denial of Preliminary Injunction in Samsung-Janssen Patent License Dispute
---
Life Sciences & Pharma
Most Significant
Third Circuit Affirms Denial of Injunction in Janssen-Samsung Stelara Biosimilar Dispute
The Third Circuit on Friday upheld a district court's refusal to enjoin Samsung Bioepis from supplying a Cigna subsidiary with a private-label version of the ustekinumab biosimilar Pyzchiva, holding that Johnson &...
Recent Articles
Third Circuit Affirms Denial of Injunction in Janssen-Samsung Stelara Biosimilar Dispute
The Third Circuit on Friday upheld a district court's refusal to enjoin Samsung Bioepis from supplying a Cigna subsidiary with a private-label version of the ustekinumab biosimilar Pyzchiva, holding that Johnson & Johnson and Janssen Biotech had not sho...
Third Circuit Affirms Denial of Preliminary Injunction in Samsung-Janssen Patent License Dispute
---